Abstract
We commend the authors on their recent publication on trends in BCG utilization during periods of temporary supply shortages. Notably, the study compares the periods 2004-2012 versus 2013-2015, which does not include the most recent announcement in 2016 by Sanofi to exit the market completely. This begs the question: if temporary shortages decrease utilization growth by half, then what will be the impact of a complete market exit?
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
